Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
Summary
Antengene received IND approval from China’s NMPA for ATG-201, a CD19/CD3 bispecific T-cell engager for B cell-related autoimmune diseases. The company plans to start the Phase I ATTRACT study in China soon and prepare parallel clinical development in Australia. Antengene also has a worldwide exclusive license arrangement with UCB, which will take over further clinical development after the first-in-human trials. The approval marks a strategic expansion of Antengene’s pipeline beyond oncology and hematology into autoimmune disease.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected